Log in to search using one of your social media accounts:

 

He Treated The Very First Ebola Cases 40 Years Ago. Then He Watched The World Forget.
This article is part of HuffPost’s Project Zero campaign, a yearlong series on neglected tropical diseases and efforts to fight them. KINSHASA, Congo ― In early 2014, few people worried that the Ebola virus, which is up to 90 percent fatal, would pose a global threat. So the World Health Organization sent shockwaves around the world when it announced that Ebola was spreading out of control in West Africa. Before the epidemic was over two years later, it had killed thousands of people. They died in terrifying and painful ways, often passing the disease on to family members before and even after death....
Source: Healthy Living - The Huffington Post - March 24, 2017 Category: Consumer Health News Source Type: news

He Treated The Very First Ebola Cases 40 Years Ago. Then He Watched The World Forget.
This article is part of HuffPost’s Project Zero campaign, a yearlong series on neglected tropical diseases and efforts to fight them. KINSHASA, Congo ― In early 2014, few people worried that the Ebola virus, which is up to 90 percent fatal, would pose a global threat. So the World Health Organization sent shockwaves around the world when it announced that Ebola was spreading out of control in West Africa. Before the epidemic was over two years later, it had killed thousands of people. They died in terrifying and painful ways, often passing the disease on to family members before and even after death....
Source: Science - The Huffington Post - March 24, 2017 Category: Science Source Type: news

Silence is golden -- Suppressing host response to Ebola virus may help to control infection
(Boston University Medical Center) The Ebola virus causes a severe, often fatal illness when it infects the human body. Initially targeting cells of the immune system called macrophages, white blood cells that absorb and clear away pathogens, a new study has found a way to potentially 'silence' these Ebola virus-infected macrophages.The findings, which appear in the Journal of Virology, could lead to new treatment options for Ebola virus disease. (Source: EurekAlert! - Infectious and Emerging Diseases)
Source: EurekAlert! - Infectious and Emerging Diseases - March 22, 2017 Category: Infectious Diseases Source Type: news

Rapid Risk Assessment: Human Infection with Avian Influenza A(H7N9) Virus; Fifth Update, 27 January 2017
European Union, European Centre for Disease Prevention and Control. 01/27/2017 This 14-page rapid risk assessment aims to summarize the epidemiological and virological information on human infections with avian influenza A(H7N9) viruses following an upsurge in cases since December 2016 in China. It provides background on the clinical aspects, spectrum of disease, and treatment of the disease. It assesses the risk to public health in the European Union/European Economic Area (EU/EEA) and to EU/EEA citizens. At present, the most immediate threat to EU citizens is to those living or visiting influenza A(H7N9)-affected areas i...
Source: Disaster Lit: Resource Guide for Disaster Medicine and Public Health - March 12, 2017 Category: Global & Universal Authors: The U.S. National Library of Medicine Source Type: news

Vitamin D decreases HCV cell replication & aids virologic response
Vitamin D decreased hepatitis C cell replication and appeared significantly associated with rapid virologic response in anti-viral therapy, according to study results published inHepatology Research.Healio (Source: Society for Endocrinology)
Source: Society for Endocrinology - March 1, 2017 Category: Endocrinology Source Type: news

Early Age at Start of ART for Better Virologic Control Early Age at Start of ART for Better Virologic Control
Initiating ART earlier in life may help improve virologic outcomes among infants and children with HIV.AIDS (Source: Medscape Hiv-Aids Headlines)
Source: Medscape Hiv-Aids Headlines - February 20, 2017 Category: Infectious Diseases Tags: HIV/AIDS Journal Article Source Type: news

Japanese Journal of Infectious Diseases (JJID)
An open-access journal from the National Institute of Infectious Diseases which publishes bimonthly on basic research on infectious diseases relevant to humans in the fields of bacteriology, virology, mycology, parasitology, medical entomology, vaccination, and toxicology, pathology, immunology, biochemistry, and blood safety. (Source: PHPartners.org)
Source: PHPartners.org - February 10, 2017 Category: Global & Universal Source Type: news

The Journal of Veterinary Diagnostic Investigation (JVDI)
JVDI is devoted to all aspects of veterinary laboratory diagnostic science, including anatomic pathology, bacteriology/mycology, clinical pathology, epidemiology, immunology, laboratory information management, molecular biology, parasitology, public health, toxicology, and virology. Content is open access after a 12-month embargo. (Source: PHPartners.org)
Source: PHPartners.org - February 10, 2017 Category: Global & Universal Source Type: news

Highlighting the clinical complications associated with ART in HIV/TB coinfected patients
(Future Science Group) Today Future Science Group announces the publication of an article in Future Virology highlighting the clinical complications associated with antiretroviral therapy in Chinese HIV/ Tuberculosis (TB) coinfected patients. (Source: EurekAlert! - Infectious and Emerging Diseases)
Source: EurekAlert! - Infectious and Emerging Diseases - February 10, 2017 Category: Infectious Diseases Source Type: news

Nigeria: Govt Dismisses HIV/Aids Cure Claims
[Guardian] The Federal Government through the National Agency for the Control of AIDS (NACA) and the Nigeria Centre for Disease Control (NCDC) has dismissed the claims by a Professor of Veterinary Medicine and Clinical Virology at the Michael Okpara University of Agriculture Umudike, Abia State, Maduike Ezeibe, to have discovered a new drug for the cure of Human Immuno-deficiency Virus (HIV)/Acquired Immune Deficiency Syndrome (AIDS). (Source: AllAfrica News: HIV-Aids and STDs)
Source: AllAfrica News: HIV-Aids and STDs - February 7, 2017 Category: Infectious Diseases Source Type: news

Nigeria: NACA Dismisses HIV Cure Claim By Michael Okpara University Prof
[Vanguard] The National Agency for the Control of AIDS, NACA, has dismissed an HIV cure claim by Professor Maduike Ezeibe, a Professor of Veterinary Medicine and Clinical Virology at the Michael Okpara University of Agriculture, Abia State. (Source: AllAfrica News: HIV-Aids and STDs)
Source: AllAfrica News: HIV-Aids and STDs - February 7, 2017 Category: Infectious Diseases Source Type: news

Atomic-scale view of bacterial proteins offers path to new tuberculosis drugs
In studying a cousin of the bacterium that causes tuberculosis, scientists have drawn a molecular map of the target for rifampicin, a common antibiotic. They are now using it in an effort to combat multi-resistant tuberculosis, for which existing treatments don’t work. More » (Source: The Rockefeller University Newswire)
Source: The Rockefeller University Newswire - February 3, 2017 Category: Biomedical Science Authors: Tashian Myers Tags: Science News chemical and structural biology Elisabeth Campbell immunology RNA polymerase Seth Darst tuberculosis Virology and Microbiology Source Type: news

Discovery helps explain why only some people develop life-threatening dengue infections
After contracting dengue fever once, certain people who encounter the virus again develop much more severe infections. New research identifies an immunological signature that could help identify and better treat these patients. More » (Source: The Rockefeller University Newswire)
Source: The Rockefeller University Newswire - January 31, 2017 Category: Biomedical Science Authors: Wynne Perry Tags: Science News antibody-dependent enhancement dengue Fc region immunology Jeffrey Ravetch Jeffrey V. Ravetch Leonard Wagner Laboratory of Molecular Genetics and Immunology Taia Wang Virology Source Type: news

This Is When You're Most Likely To Catch The Flu
If you’re wondering when you might get the flu, a new study indicates you should keep an eye on your local weather report. According to research published in the Journal of Clinical Virology, a season’s first cold snap below 37 degrees Fahrenheit (or zero degrees Celsius, as defined in the study) preceded a mass spread of the flu in Gothenberg, a large metropolitan area of Sweden. The researchers suggest that if you keep your eye on the weather and watch for the first major dip in the temperature, you can essentially mark your calendar in anticipation for an influx of the illness.  “We believe that t...
Source: Healthy Living - The Huffington Post - January 26, 2017 Category: Consumer Health News Source Type: news

This Is Exactly When You're More Likely To Catch The Flu
By Amanda MacMillan Cases of flu are on the rise, according to a recent statement from the United States Centers for Disease Control and Prevention, and experts are warning that this year’s flu season will be worse than last. Now, a new study published in the Journal of Clinical Virology is shedding some light on exactly how cold weather and the spread of viruses are linked. It turns out, seasonal flu outbreaks first appear each year about a week after the winter’s first cold spell — or at least that’s what happened in Sweden, over the course of three years when researchers tracked weather...
Source: Healthy Living - The Huffington Post - January 17, 2017 Category: Consumer Health News Source Type: news

Scientists learn how to ramp up microbes ’ ability to make memories
Researchers have identified a mutation that prompts bacterial cells to acquire genetic memories 100 times more frequently than they do naturally. This discovery provides a powerful research tool and could bring scientists one step closer to developing DNA-based data storage devices. More » (Source: The Rockefeller University Newswire)
Source: The Rockefeller University Newswire - January 4, 2017 Category: Biomedical Science Authors: Wynne Perry Tags: Science News biotechnology Cas9 CRISPR I473F immunology Laboratory of Bacteriology Luciano Marraffini microbiology Robert Heler synthetic biology Virology Source Type: news

Nigeria: Institute Urges Government to Raise Funding for HIV/Aids
[Guardian] Abuja -The Institute of Human Virology Nigeria has called on the Federal Government to develop a pool of fund to enable it to cope with the HIV/AIDS epidemic in the country instead of relying on grants from donors and partners. (Source: AllAfrica News: HIV-Aids and STDs)
Source: AllAfrica News: HIV-Aids and STDs - December 27, 2016 Category: Infectious Diseases Source Type: news

Janssen reports positive results in Phase III combination trial to treat HIV
Janssen Sciences Ireland (Janssen) has reported positive results in the first of the two Phase III studies that evaluate the safety and efficacy of switching virologically suppressed patients from a three or four drug anti-retroviral regimen to the t … (Source: Drug Development Technology)
Source: Drug Development Technology - December 21, 2016 Category: Pharmaceuticals Source Type: news

Advanced Cirrhosis Patients Respond to DAAs in Real-world Study
High sustained virologic response rates were seen among patients with decompensated cirrhosis in European compassionate care cohort. (Source: ConsultantLive)
Source: ConsultantLive - December 7, 2016 Category: Internal Medicine Authors: Mark L. Fuerst Tags: Hepatitis C Source Type: news

UTMB researchers find how Ebola disables the immune system
(University of Texas Medical Branch at Galveston) A new study at The University of Texas Medical Branch in Galveston sheds light on how Ebola so effectively disables the human immune system. Virologist Alex Bukreyev, UTMB professor and senior author of the study, said the research team engineered versions of the Ebola virus in order to study how the components responsible for thwarting or disabling our immune defenses wreak their havoc. The findings are described in the new edition of PLOS Pathogens. (Source: EurekAlert! - Infectious and Emerging Diseases)
Source: EurekAlert! - Infectious and Emerging Diseases - December 6, 2016 Category: Infectious Diseases Source Type: news

Occult HCV May Persist in Treated Patients After Liver Transplant Occult HCV May Persist in Treated Patients After Liver Transplant
Despite a sustained virologic response for 12 weeks (SVR12) to direct-acting antiviral agents for recurrent hepatitis C virus (HCV) infection following liver transplantation, some patients continue to have occult infection.Reuters Health Information (Source: Medscape Transplantation Headlines)
Source: Medscape Transplantation Headlines - December 2, 2016 Category: Transplant Surgery Tags: Gastroenterology News Source Type: news

Pterosaurs Hijack Royal Society Evo Meeting
Image: Life in Utah; or, the Mysteries and Crimes of Mormonism, J. H. Beadle (1870) I brought some copies of my book, Royal Society: The Public Evolution Summit to London and passed them around the gathering of distinguished evolution enthusiasts at 7 Carlton House Terrace, anticipating that the November 7-9 Royal Society "new trends" conference would fall short of its billing. Indeed, one of the opening speakers referred to himself as representing the Jurassic Age of science and pointed out that the content of the previous speaker's lecture -- which put more than the jet-lagged in the audience to sleep...
Source: Science - The Huffington Post - November 22, 2016 Category: Science Source Type: news

Nigeria: Who Donates Polio Modular Laboratory to UCH
[Premium Times] The World Health Organisation, WHO, will on Friday hand over a new Modular Polio Laboratory to the premier polio laboratory in the Department of Virology, University of Ibadan, Oyo State. (Source: AllAfrica News: Health and Medicine)
Source: AllAfrica News: Health and Medicine - November 18, 2016 Category: African Health Source Type: news

Virologists unravel mystery of late C20th gibbon leukaemia outbreak
(University of Nottingham) The mystery of an outbreak of lymphoma and leukaemia in gibbon colonies in the US, Bermuda and Thailand in the late 1960s and early 1970s has been solved by animal disease detectives at The University of Nottingham. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - November 17, 2016 Category: Cancer & Oncology Source Type: news

Nigeria: WHO Donates Polio Lab to Uniibadan
[Daily Trust] The World Health Organization (WHO) will hand over a new modular polio laboratory to Nigeria's premier polio laboratory in the Department of Virology, University of Ibadan, Oyo state Friday. (Source: AllAfrica News: Health and Medicine)
Source: AllAfrica News: Health and Medicine - November 16, 2016 Category: African Health Source Type: news

Virological Response of Daclatasvir Plus Sofosbuvir for HCV Virological Response of Daclatasvir Plus Sofosbuvir for HCV
The results of this study support a regimen of daclatasvir plus sofosbuvir, with or without ribavirin, in patients with chronic HCV infection, including those with severe liver disease.Gut (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - November 16, 2016 Category: Consumer Health News Tags: Gastroenterology Journal Article Source Type: news

DAA Combination Confirmed Highly Effective Against HCV in Real-word Setting
Sustained virologic response was seen in 99% of subjects, reflecting rates seen in pre-registration studies. Adverse events were mild. (Source: ConsultantLive)
Source: ConsultantLive - November 14, 2016 Category: Internal Medicine Authors: Mark L. Fuerst Tags: Hepatitis C Source Type: news

DAA Combination Confirmed Highly Effective Against HCV in Real-world Setting
Sustained virologic response was seen in 99% of subjects, reflecting rates seen in pre-registration studies. Adverse events were mild. (Source: ConsultantLive)
Source: ConsultantLive - November 14, 2016 Category: Internal Medicine Authors: Mark L. Fuerst Tags: Hepatitis C Source Type: news

Merck Announces Findings for Investigational Triple-Combination Chronic Hepatitis C Therapy Showing High Rates of Sustained Virologic Response in People with Genotypes 1, 2 or 3 Infection
Dateline City: KENILWORTH, N.J. Phase 2 Data Presentations at The Liver Meeting® Detail SVR12 Rates from Two Studies as Well as SVR8 Rates in Patients for Whom Direct-Acting Antiviral Treatment Previously FailedKENILWORTH, N.J.--(BUSINESS WIRE)--Merck (NYSE:MRK), known as MSD outside of the United States and Canada, today announced the presentation of results from three Phase 2 clinical trials evaluating MK-3682B (MK-3682/grazoprevir/ruzasvir1), the company ’s investigational all-oral, triple-combination regimen for the treatment of chronic hepatitis C (HCV) infection (informally referred ...
Source: Merck.com - Corporate News - November 13, 2016 Category: Pharmaceuticals Tags: Hepatitis C Newsroom Corporate News Latest News #Merck #MRK $MRK MSD Source Type: news

A Promising Study Reveals New Hope For An HIV Cure
A new experimental HIV vaccine, when combined with a compound that stimulates a person’s immune system, demonstrated potential for a path to curing HIV. The small study, involving rhesus monkeys who had the monkey equivalent of HIV, revealed that this novel combination was effective at suppressing the virus to undetectable levels in a few of the subjects, without the need for antiretroviral treatments.  If the combination of the HIV vaccine and immune system compound is shown to be effective in people, it could mean one step toward a cure for HIV, said lead investigator Dan Barouch, director for the Center for V...
Source: Healthy Living - The Huffington Post - November 11, 2016 Category: Consumer Health News Source Type: news

A Promising Study Reveals New Hope For An HIV Cure
A new experimental HIV vaccine, when combined with a compound that stimulates a person’s immune system, demonstrated potential for a path to curing HIV. The small study, involving rhesus monkeys who had the monkey equivalent of HIV, revealed that this novel combination was effective at suppressing the virus to undetectable levels in a few of the subjects, without the need for antiretroviral treatments.  If the combination of the HIV vaccine and immune system compound is shown to be effective in people, it could mean one step toward a cure for HIV, said lead investigator Dan Barouch, director for the Center for V...
Source: Science - The Huffington Post - November 11, 2016 Category: Science Source Type: news

Investigational HIV therapeutic vaccine found to control SIV in preclinical studies
Researchers have found that an investigational treatment combining therapeutic vaccine and an immune stimulator was successful for improving virologic control and delay viral rebound after the discontinuation of anti-retroviral therapy (ART). (Source: Pharmaceutical Technology)
Source: Pharmaceutical Technology - November 11, 2016 Category: Pharmaceuticals Source Type: news

Predators can drive increase in virus populations, new study shows
(University of Nebraska-Lincoln) In what scientists say could be a potential 'game-changer' in the study of virology, a new study shows that a predator's consumption of prey can catalyze the natural rise and fall of chlorovirus populations. (Source: EurekAlert! - Biology)
Source: EurekAlert! - Biology - November 10, 2016 Category: Biology Source Type: news

Investigational HIV therapeutic vaccine approach helps control SIV in preclinical studies
(The U.S. Military HIV Research Program (MHRP)) An investigational treatment combination of a therapeutic vaccine and an immune-stimulator improves virologic control and delays viral rebound following the discontinuation of antiretroviral therapy in non-human primates infected with SIV. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - November 9, 2016 Category: Global & Universal Source Type: news

NCI grant funds SMU research into cancer-causing viruses that hide from the immune system
(Southern Methodist University) The National Cancer Institute is funding research at Southern Methodist University, Dallas, into cancer-causing viruses that hide from the immune system. Genes common to both the human T-cell leukemia virus and high-risk human papillomaviruses activate survival mechanisms in cancer cells. SMU virologist and cancer researcher Robert Harrod leads his lab's effort to find ways to inhibit those genes to halt the development of cancer. The hope is to ultimately develop a chemotherapy drug. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - November 8, 2016 Category: Global & Universal Source Type: news

A Virus Mutation Is What Made The 2014 Ebola Outbreak So Deadly
The Ebola outbreak that devastated West Africa in 2014 was a product of multiple factors, including a population that relies increasingly on global travel, poverty and inadequate public health infrastructure on the ground and local burial practices that conflicted with medical advice. Now, we know about another factor that helped the outbreak spread: the virus mutated. Mutation is standard among viruses, and according to two cell model studies published in the journal Cell in November, an Ebola mutation may have allowed the virus to infect humans more easily than the original. The 2014 outbreak resulted in approximate...
Source: Science - The Huffington Post - November 4, 2016 Category: Science Source Type: news

A Virus Mutation Is What Made The 2014 Ebola Outbreak So Deadly
The Ebola outbreak that devastated West Africa in 2014 was a product of multiple factors, including a population that relies increasingly on global travel, poverty and inadequate public health infrastructure on the ground and local burial practices that conflicted with medical advice. Now, we know about another factor that helped the outbreak spread: the virus mutated. Mutation is standard among viruses, and according to two cell model studies published in the journal Cell in November, an Ebola mutation may have allowed the virus to infect humans more easily than the original. The 2014 outbreak resulted in approximate...
Source: Healthy Living - The Huffington Post - November 4, 2016 Category: Consumer Health News Source Type: news

Ebola Virus Mutated to Become More Infectious, Scientists Say
Virologists hope this information will help them better prepare for the next outbreak Source: HealthDay Related MedlinePlus Page: Ebola (Source: MedlinePlus Health News)
Source: MedlinePlus Health News - November 3, 2016 Category: Consumer Health News Source Type: news

Strongest Evidence Yet for Zika Link to Guillain-Barre Strongest Evidence Yet for Zika Link to Guillain-Barre
A new study has shown the presence of Zika virus on PCR virologic testing in Colombian patients with Guillain-Barre syndrome.Medscape Medical News (Source: Medscape Neurology and Neurosurgery Headlines)
Source: Medscape Neurology and Neurosurgery Headlines - October 6, 2016 Category: Neurology Tags: Neurology & Neurosurgery News Source Type: news

New insight into course and transmission of Zika infection
(Beth Israel Deaconess Medical Center) In one of the first and largest studies of its kind, a research team lead by virologists at Beth Israel Deaconess Medical Center has characterized the progression of two strains of the viral infection. The study, published online this week in Nature Medicine, revealed Zika's rapid infection of the brain and nervous tissues, and provided evidence of risk for person-to-person transmission. (Source: EurekAlert! - Infectious and Emerging Diseases)
Source: EurekAlert! - Infectious and Emerging Diseases - October 6, 2016 Category: Infectious Diseases Source Type: news

HCV Eradication, Gut Dysbiosis, and Inflammation in Cirrhosis HCV Eradication, Gut Dysbiosis, and Inflammation in Cirrhosis
This study aimed to determine the impact of sustained virological response on gut dysbiosis and systemic inflammation in patients with cirrhosis due to HCV.Alimentary Pharmacology & Therapeutics (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - October 4, 2016 Category: Consumer Health News Tags: Gastroenterology Journal Article Source Type: news

Study explains how an intestinal microbe protects against other, more dangerous bacteria
Working in animal models, scientists have found that an enzyme produced by one microbe can shield the gut against attack from other, more harmful bacteria. The findings could potentially inform the design of new probiotics for use against dangerous pathogens like those spreading hospital-acquired infections. More » (Source: The Rockefeller University Newswire)
Source: The Rockefeller University Newswire - October 3, 2016 Category: Biomedical Science Authors: Geoffrey Shearer Tags: Science News Clostridium difficile Daniel Mucida Enterococcus faecium Howard Hang immunology Kavita Rangan microbiology microbiome probiotics Virginia Pedicord Virology Source Type: news

[This Week in Science] Modeling hepatitis A in mice
Author: Kristen L. Mueller (Source: ScienceNOW)
Source: ScienceNOW - September 29, 2016 Category: Science Authors: Kristen L. Mueller Tags: Virology Source Type: news

Scientists uncover a clever ranking strategy bacteria use to fight off viruses
Like humans, bacteria come under attack from viruses—and their immune systems, like ours, are capable of remembering a virus so as to preempt any future invasion. New research explores how the bacterial immune system CRISPR stores and ranks these memories. More » (Source: The Rockefeller University Newswire)
Source: The Rockefeller University Newswire - September 19, 2016 Category: Biomedical Science Authors: Wynne Perry Tags: Science News biotechnology CRISPR immunology Jon McGinn Laboratory of Bacteriology Luciano Marraffini microbiology phage Virology Source Type: news

In the News – New York Times – Rice
Lasker Awards Given for Work in Physiology, Virology and Science Education   “At the time, researchers thought the work might be as simple as inserting that newly sequenced RNA into cultured cells and watching it replicate. But in experiment after … More » (Source: The Rockefeller University Newswire)
Source: The Rockefeller University Newswire - September 13, 2016 Category: Biomedical Science Authors: Katie Fenz Tags: In the News Charles M. Rice hepatitis C Lasker Award Lasker Award for Clinical Medical Research Lasker-DeBakey Clinical Medical Research Award Source Type: news

Lasker Awards Given for Work in Physiology, Virology and Science Education
This year ’ s honors speak to the additive nature of scientific research, with prizes recognizing people who built on the findings of others. (Source: NYT Health)
Source: NYT Health - September 13, 2016 Category: Consumer Health News Authors: STEPH YIN Tags: Lasker Awards Hepatitis hematology Alberts, Bruce M Kaelin, William G. Ratcliffe, Peter J. Semenza, Gregg L. Bartenschlager, Ralf F. W. Rice, Charles M. Sofia, Michael J. Source Type: news

Charles M. Rice wins Lasker Award for groundbreaking work on the hepatitis C virus
This year’s Lasker-DeBakey Clinical Medical Research Award honors Charles M. Rice, who developed a system to study the replication of the virus that causes hepatitis C, an advance that has led to safe and powerful new drugs that cure the disease. The award, considered the most coveted American prize in medical science, will be presented on September 23 in New York City. More » (Source: The Rockefeller University Newswire)
Source: The Rockefeller University Newswire - September 13, 2016 Category: Biomedical Science Authors: Geoffrey Shearer Tags: Awards and Honors Charles M. Rice hepatitis C hepatitis C virus Laboratory of Virology and Infectious Disease Lasker Award Lasker Award for Clinical Medical Research Lasker-DeBakey Clinical Medical Research Award Source Type: news

HCV Treatment Failure and Risk of Hepatocellular Carcinoma HCV Treatment Failure and Risk of Hepatocellular Carcinoma
Are patients with hepatitis C who receive antiviral treatment but fail to achieve sustained virological response more likely to develop hepatocellular carcinoma than untreated patients?Journal of Viral Hepatitis (Source: Medscape Radiology Headlines)
Source: Medscape Radiology Headlines - September 9, 2016 Category: Radiology Tags: Gastroenterology Journal Article Source Type: news

Danaher to buy Cepheid in $4B deal to expand in diagnostics
(Reuters) –Danaher Corp. (NYSE:DHR) said on Tuesday it would buy molecular diagnostics company Cepheid in a deal valued at $4 billion, including debt, to strengthen its diagnostics business. Danaher will pay $53 per share in cash, a premium of 54% to Cepheid’s close of $34.42 on Friday. Danaher, which develops technology for the dental, life sciences, diagnostics and environmental industries, said the addition of Cepheid would improve operational efficiencies and expand margins in its $5 billion diagnostics business. Sunnyvale, California-based Cepheid develops molecular systems and tests for institutions to pe...
Source: Mass Device - September 6, 2016 Category: Medical Equipment Authors: MassDevice Tags: Business/Financial News Mergers & Acquisitions Cepheid Danaher Corp. Source Type: news

HPV infection rates plummet after vaccine with China the next frontier
A decade after the vaccine was introduced, research shows dramatic success. Australian scientist Ian Frazer says his collaborator Jian Zhou will be ‘vindicated’ when it becomes available in the Chinese market this yearThe virologist and cancer researcher Dr Jian Zhou had an important goal after creating a vaccine for the cancer-causing human papillomavirus in a Queensland laboratory.He wanted to see the vaccine made widely available in his home country of China, which today accounts for more than 28% of the world ’s cervical cancer cases. Cervical cancer is also the second most common cancer in Chinese wo...
Source: Guardian Unlimited Science - September 4, 2016 Category: Science Authors: Melissa Davey Tags: HPV vaccine Health Vaccines and immunisation Cancer Science Health (Australia) China Australia news Medical research Source Type: news